Open AccessThe Therapeutic Potential of Candoxatril, a Neutral Endopeptidase Inhibitor, in Humans
Author(s) -
McDowell Garry,
Nicholls D. Paul
Publication year - 2000
Publication title -
cardiovascular drug reviews
Language(s) - English
Resource type - Journals
eISSN - 1527-3466
pISSN - 0897-5957
DOI - 10.1111/j.1527-3466.2000.tb00051.x
Subject(s) - neprilysin , prodrug , medicine , pharmacology , pharmacokinetics , heart failure , pharmacodynamics , angiotensin converting enzyme , ace inhibitor , chronic hypertension , orally active , dobutamine , enzyme inhibitor , drug , enzyme , chemistry , hemodynamics , oral administration , biochemistry , biology , blood pressure , pregnancy , preeclampsia , genetics
Candoxatril (UK‐79,300) is the orally active prodrug of candoxatrilat (UK‐73,967), the active enantiomer of (±) candoxatrilat (UK‐69,578), a potent neutral endopeptidase inhibitor. This article describes the rationale behind the use of this drug in the treatment of hypertension and chronic heart failure in humans. It further describes the pharmacokinetic and pharmacodynamics of candoxatril in preclinical animal studies, normal healthy individuals, and in patients with hypertension and chronic cardiac failure. In addition, we have described the initial results of clinical trials in hypertension and chronic cardiac failure, together with the potential future clinical developments of combined neutral endopeptidase/angiotensin converting enzyme inhibitors.